Congo is living through the fastest-starting Ebola outbreak anyone has recorded, and the vaccine the world spent a decade celebrating is sitting in a freezer. As of June 21, health authorities in Ituri province had confirmed 1,003 cases and 254 deaths, the worst opening month of any Ebola epidemic on record. Neither the licensed vaccine nor the two antibody drugs that turned Ebola from a near-certain death sentence into a survivable disease are being deployed. They were all built for a different virus than the one doing the killing.
For most people who lived through the last decade of Ebola headlines, the story had closed on a win. After the West African catastrophe of 2014, the world finally built the weapon: Ervebo, a single-dose vaccine approved by the FDA in 2019, which ring-vaccinated its way through the 2018 to 2020 outbreak in eastern Congo, the second-largest Ebola epidemic in history. Add two monoclonal-antibody drugs that drove mortality from better than even odds of dying down to about a third in the trial that earned them approval, and the public takeaway settled into something simple: Ebola is handled now. We have the shot. We have the drugs.
We did beat Ebola. We beat one species of it. The outbreak in Ituri is caused by another, and the gap between what “we beat Ebola” implies and what a glycoprotein actually permits is exactly the gap now playing out in Congo.
A different species, by a few crucial letters
To see the problem, go back to a small district in western Uganda. In November 2007, doctors there confronted an outbreak of hemorrhagic fever that lab work eventually pinned on something new: a fifth species of ebolavirus, named Bundibugyo after the district where it surfaced. That first outbreak ran to 56 confirmed cases with a fatality rate around 40 percent, lethal but well below the 80 to 90 percent that Zaire ebolavirus has reached in its worst years. Bundibugyo got filed away as a rarity. It had surfaced only a handful of times since.
It is the virus now in Ituri.
Ervebo, the vaccine everyone remembers from the good-news cycle, is a feat of genetic engineering aimed at exactly one target: the surface glycoprotein of Zaire ebolavirus, the molecular handle the virus uses to break into a cell. The immune response it trains is keyed to that one protein. Bundibugyo’s glycoprotein is different enough that the trained response does not reliably recognize it. The CDC is blunt about the consequence: Ervebo is licensed against Zaire ebolavirus only, and based on animal studies it is not expected to protect against Bundibugyo. The WHO has not deployed it in this outbreak.
The same species mismatch sidelines the drugs. Inmazeb and Ebanga, the antibody cocktails that earned approval in 2020, are both tuned to the Zaire glycoprotein. Against Bundibugyo there is no approved vaccine and no approved treatment. What responders have instead is supportive care, fluids, and a scramble to test candidates under emergency research protocols. The countermeasures we celebrated worked. They were also narrow, built lock-and-key for one species while four others kept circulating in the same forests.
The virus is not the only thing spreading
Even a perfectly matched Bundibugyo vaccine sitting in that freezer might not contain this outbreak, because what is fueling it is not virological. It is the collapse of everything around the patient.
Ituri sits in a stretch of eastern Congo where armed groups, including an Islamic State-aligned militia, have cut off villages, emptied them at gunpoint, and driven terrified people into overcrowded displacement camps where one introduction becomes a wildfire. Contact tracing, the unglamorous backbone of every Ebola response that has ever worked, has buckled. Responders are reaching only about 55 percent of known contacts, leaving more than 35,000 untraced. Africa CDC’s director general, Dr. Jean Kaseya, named the deeper hole: “If you want to control an outbreak, especially Ebola, you must know the index case. We don’t have confidence on when this outbreak started.” Months in, no one has found patient zero.
We have watched this dynamic before, and it is worth remembering the full bill. During the 2018 to 2020 Congo outbreak, the emergency did not only kill through Ebola. It swallowed the region’s health resources whole, and deaths from malaria, measles, and cholera climbed as the system bent toward a single disease. The confirmed Ebola count always undercounts the real damage. When a war zone’s thin medical infrastructure pivots entirely to one virus, the people who die of everything else never reach the dashboard.
What to watch next
Science did not fail here. The vaccine and the antibody drugs were triumphs that would have read as fantasy in 2014. What failed was the public translation. “We beat Ebola” was never true in the universal sense people absorbed it: we beat one species, and we are now watching in real time what it looks like when a different one arrives in the worst possible place.
Three things will tell you where this goes. First, whether the experimental treatments now in trials show any signal against Bundibugyo, because that, not a press release, is what changes the survival math. Second, that contact-tracing percentage, the truest leading indicator of whether the curve bends or keeps climbing. And third, the border: Uganda has already confirmed Bundibugyo cases and a death in a patient who traveled from Congo, the same way the virus first walked out of Bundibugyo District nearly twenty years ago. The strain came from there. The lesson should have traveled with it.
Sources
- STAT – Confirmed Ebola cases in Congo outbreak top 1,000 with 254 deaths
- CDC – Ebola Disease Outbreak in the DRC and Uganda (Health Alert Network notice)
- WHO – Ebola disease caused by Bundibugyo virus, DRC & Uganda (Disease Outbreak News)
- Emerging Infectious Diseases (CDC) – Proportion of Deaths and Clinical Features in Bundibugyo Ebola Virus Infection, Uganda
- NEJM (2019) – A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics (PALM trial)
- CBS News – Ebola strain in Congo-Uganda outbreak has no vaccine or treatment
- CEPI – Bundibugyo Virus: what it is and what it is not
- UN News – DRC Ebola outbreak: hundreds of suspected cases, no vaccine
- BMJ (2019) – Congo sees rise in deaths from malaria, measles, and cholera as Ebola outbreak swallows up resources
- Wikipedia – 2026 Central Africa Ebola epidemic (case timeline, conflict context)